In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Gemphire Therapeutics (NASDAQ: GEMP), with a price target of $6. The company’s shares opened today at $1.61, close to its 52-week low of $0.83.
Newman said:
“We expect the study to continue under higher safety scrutiniy, and will carefully watch for any changes.”
According to TipRanks.com, Newman is a 5-star analyst with an average return of 17.3% and a 46.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Atara Biotherapeutics.
Gemphire Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.43 and a one-year low of $0.83. Currently, Gemphire Therapeutics has an average volume of 723.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.
Read More on GEMP:
